Related references
Note: Only part of the references are listed.Early Growth Retardation and Insulin Resistance in JAZF1 KO Mice
Hui-Young Lee et al.
DIABETES (2011)
Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects
S. Sha et al.
DIABETES OBESITY & METABOLISM (2011)
SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule
Volker Vallon et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function
Michael J. Jurczak et al.
DIABETES (2011)
Familial Renal Glucosuria and SGLT2: From a Mendelian Trait to a Therapeutic Target
Rene Santer et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus
Sunil Nair et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Discovery of Canagliflozin, a Novel C-Glucoside with Thiophene Ring, as Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Sumihiro Nomura et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
Clifford J. Bailey et al.
LANCET (2010)
SGLT2 inhibition - a novel strategy for diabetes treatment
Edward C. Chao et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Renal glucose transporters: novel targets for hyperglycemia management
Amanda Mather et al.
NATURE REVIEWS NEPHROLOGY (2010)
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
James F. List et al.
DIABETES CARE (2009)
A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers Applicability of a novel insulin-independent treatment
John P. H. Wilding et al.
DIABETES CARE (2009)
Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies
S. Del Prato
DIABETIC MEDICINE (2009)
Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats
Yoshikazu Fujimori et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications
George L. Bakris et al.
KIDNEY INTERNATIONAL (2009)
Mutation of solute carrier SLC16A12 associates with a syndrome combining juvenile cataract with microcornea and renal glucosuria
Barbara Kloeckener-Gruissem et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2008)
Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats
Songping Han et al.
DIABETES (2008)
The role for endoplasmic reticulum stress in diabetes mellitus
Decio L. Eizirik et al.
ENDOCRINE REVIEWS (2008)
Na+-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels:: Involvement of hepatocyte nuclear factor-1α expression and activity
H. S. Freitas et al.
ENDOCRINOLOGY (2008)
Is glycemic control improving in US adults?
Thomas J. Hoerger et al.
DIABETES CARE (2008)
Imino sugars are potent agonists of the human glucose sensor SGLT3
Andrew A. Voss et al.
MOLECULAR PHARMACOLOGY (2007)
Active sugar transport in health and disease
E. M. Wright et al.
JOURNAL OF INTERNAL MEDICINE (2007)
Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes - results of a hyperglycaemic glucose clamp study
Klaus Rave et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2006)
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
H Rahmoune et al.
DIABETES (2005)
Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki rats
K Ueta et al.
LIFE SCIENCES (2005)
Phlorizin: a review
JRL Ehrenkranz et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2005)
Global prevalence of diabetes - Estimates for the year 2000 and projections for 2030
S Wild et al.
DIABETES CARE (2004)
A glucose sensor hiding in a family of transporters
A Díez-Sampedro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes
AE Butler et al.
DIABETES (2003)
Beneficial effect of T-1095, a selective inhibitor of renal Na+-glucose cotransporters, on metabolic index and insulin secretion in spontaneously diabetic GK rats
K Nunoi et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2002)
Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat
S Vestri et al.
JOURNAL OF MEMBRANE BIOLOGY (2001)
Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na+-glucose cotransporter inhibitor T-1095
K Arakawa et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Antidiabetic effect of T-1095, an inhibitor of Na+-glucose cotransporter, in neonatally streptozotocin-treated rats
A Oku et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
Share Paper
